Cargando…

Outcomes after transvenous defibrillator implantation in cardiac sarcoidosis: A systematic review

INTRODUCTION: Sarcoidosis is a systemic inflammatory disorder associated with ventricular arrhythmias (VAs) and sudden death in the context of cardiac involvement. Guidelines advocate implantable cardioverter‐defibrillator (ICD) implantation in specific subcohorts, but there is a paucity of data on...

Descripción completa

Detalles Bibliográficos
Autores principales:	Taha, Ahmed, Assaf, Omar, Champsi, Asgher, Nadarajah, Ramesh, Patel, Peysh A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2022
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9535799/ https://www.ncbi.nlm.nih.gov/pubmed/36237869 http://dx.doi.org/10.1002/joa3.12753

Ejemplares similares

A real‐world experience of subcutaneous and transvenous implantable cardiac defibrillators—comparison with the PRAETORIAN study
por: Khanra, Dibbendhu, et al.
Publicado: (2022)

Cardiac Sarcoidosis: Indications for Implantable Cardioverter-Defibrillator Therapy
por: Yalta, Kenan, et al.
Publicado: (2022)

Epicardial vs. transvenous implantable cardioverter defibrillators in children
por: Le Bos, Pierre Antoine, et al.
Publicado: (2023)

Risk Factors and Temporal Trends of Complications Associated With Transvenous Implantable Cardiac Defibrillator Leads
por: Koneru, Jayanthi N., et al.
Publicado: (2018)

Comparative outcomes of subcutaneous and transvenous cardioverter-defibrillators
por: Liang, Jin-Jun, et al.
Publicado: (2019)

Subcutaneous implantable cardioverter-defibrillator placement in a patient with a preexisting transvenous implantable cardioverter-defibrillator
por: Jazayeri, Mohammad-Ali, et al.
Publicado: (2017)

A sustained ventricular tachycardia overlooked by subcutaneous implantable cardioverter-defibrillator but recognized by co-implanted transvenous implantable cardioverter defibrillator
por: Goto, Kentaro, et al.
Publicado: (2020)

Forces Applied during Transvenous Implantable Cardioverter Defibrillator Lead Removal
por: Lennerz, Carsten, et al.
Publicado: (2014)

Transvenous Implantable Cardioverter-Defibrillator Lead Reliability: Implications for Postmarket Surveillance
por: Kramer, Daniel B, et al.
Publicado: (2015)

State‐of‐the‐art consensus on non‐transvenous implantable cardioverter‐defibrillator therapy
por: Schukro, Christoph, et al.
Publicado: (2020)

Impairment of Quality of Life in Patients with Implanted Subcutaneous Cardioverter Defibrillator (S-ICD) Compared to Implanted Transvenous Cardioverter Defibrillator Therapy
por: Thienel, Manuela, et al.
Publicado: (2022)

Prevalence of Echocardiographic Features Suggesting Cardiac Sarcoidosis in Patients With Pacemaker or Implantable Cardiac Defibrillator
por: Sun, Byung Joo, et al.
Publicado: (2011)

Clinical outcomes of subcutaneous vs. transvenous implantable defibrillator therapy in a polymorbid patient cohort
por: Kattih, Badder, et al.
Publicado: (2022)

Reply to Yalta and Yetkin—Cardiac Sarcoidosis: Indications for Implantable Cardioverter-Defibrillator Therapy
por: Duffett, Stephen A., et al.
Publicado: (2022)

Transvenous shock‐only implantable cardioverter defibrillator after an atrio‐pulmonary Fontan surgery
por: Toyohara, Keiko, et al.
Publicado: (2020)

Efficacy, safety, and in-hospital outcomes of subcutaneous versus transvenous implantable defibrillator therapy: A meta-analysis and systematic review
por: Chen, Chao-Feng, et al.
Publicado: (2019)

Comparison of quality-of-life measures in patients with transvenous and subcutaneous implantable cardioverter-defibrillators
por: Ferrick, Aileen M., et al.
Publicado: (2023)

Clinical course of hypertrophic cardiomyopathy patients implanted with a transvenous or subcutaneous defibrillator
por: Francia, Pietro, et al.
Publicado: (2023)

Sudden Cardiac Death in Children Affected by Cardiomyopathies: An Update on Risk Factors and Indications at Transvenous or Subcutaneous Implantable Defibrillators
por: Rella, Valeria, et al.
Publicado: (2020)

Lead failure in transvenous implantable cardioverter defibrillator: a new opportunity for an effective management
por: Pignalberi, Carlo, et al.
Publicado: (2018)

Comparison of complications and shocks in paediatric and young transvenous and subcutaneous implantable cardioverter-defibrillator patients
por: Quast, A. B. E., et al.
Publicado: (2018)

Hybrid subcutaneous and transvenous approach for cardiac resynchronization defibrillator implant in a patient with congenital heart disease and tricuspid bioprosthetic
por: Nabavizadeh, Pooneh, et al.
Publicado: (2019)

Transvenous implantable cardioverter-defibrillator implantation in a patient with arrhythmogenic cardiomyopathy and massive right atrial thrombus
por: Hayashi, Hiroshi, et al.
Publicado: (2020)

Leadless pacemakers – The path to safer pacing?
por: Nadarajah, Ramesh, et al.
Publicado: (2019)

Factors associated with implantable cardioverter defibrillators appropriate therapy in cardiac sarcoidosis: a meta-analysis
por: Azoulay, Levi-Dan, et al.
Publicado: (2020)

Percutaneous Extraction of Transvenous Permanent Pacemaker/Defibrillator Leads
por: Paraskevaidis, Stylianos, et al.
Publicado: (2014)

Transvenous Implantable Cardioverter‐Defibrillator (ICD) Lead Performance: A Meta‐Analysis of Observational Studies
por: Providência, Rui, et al.
Publicado: (2015)

The “Defibrillation Testing, Why Not?” survey. Testing of subcutaneous and transvenous defibrillators in the Italian clinical practice()
por: Migliore, Federico, et al.
Publicado: (2022)

Incidence and Predictors of Implantable Cardioverter-defibrillator Therapies After Generator Replacement—A Pooled Analysis of 31,640 Patients’ Data
por: Khanra, Dibbendhu, et al.
Publicado: (2022)

Management of sudden cardiac death in cardiac sarcoidosis using the wearable cardioverter defibrillator
por: Skowasch, Dirk, et al.
Publicado: (2018)

Simple and effective solution for diaphragm pacing by that uses the transvenous femoral approach in a patient treated with cardiac resynchronization-defibrillator therapy: The wrapping method
por: Alper, Ahmet Taha, et al.
Publicado: (2017)

Low-frequency attenuation filter as a reversible cause of inappropriate shocks due to myopotential oversensing
por: Patel, Peysh A., et al.
Publicado: (2021)

Left axillary active can positioning markedly reduces defibrillation threshold of a transvenous defibrillator failing to defibrillate at maximum output
por: Mitra, Raman L.
Publicado: (2018)

Subcutaneous Versus Transvenous Implantable Defibrillator Therapy: A Systematic Review and Meta‐Analysis of Randomized Trials and Propensity Score–Matched Studies
por: Fong, Khi Yung, et al.
Publicado: (2022)

High-voltage impedance rise; mechanism and management in patients with transvenous implantable cardioverter-defibrillators: a case series
por: Monkhouse, Christopher, et al.
Publicado: (2019)

Higher defibrillation threshold in methamphetamine cardiomyopathy patients with implantable cardioverter-defibrillator
por: Malhotra, Rakesh, et al.
Publicado: (2017)

Are the Four Pillars the Ideal Treatment for the Elderly?
por: Țica, Otilia, et al.
Publicado: (2023)

Discussing the Prognosis and Complications of Transvenous Lead Extraction in Patients With Cardiac Implantable Electronic Devices (CIED): A Systematic Review
por: Salib, Korlos, et al.
Publicado: (2023)

Incidence of Sudden Cardiac Death and Life-Threatening Arrhythmias in Clinically Manifest Cardiac Sarcoidosis With and Without Current Indications for an Implantable Cardioverter Defibrillator
por: Nordenswan, Hanna-Kaisa, et al.
Publicado: (2022)

Efficacy and Safety of Transvenous Lead Extraction at the Time of Upgrade from Pacemakers to Cardioverter-Defibrillators and Cardiac Resynchronization Therapy
por: Stefańczyk, Paweł, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_nap4srtgqsqfq89ugk499qrhse